Background Mepolizumab is an anti-interleukin-5 (IL-5) agent approved for EGPA at the dose of 300 mg every 4 weeks. However, from real-life studies, evidence accruing its comparable effectiveness “asthma-dose” 100 The preferred approach our center to start mepolizumab mg/4 weeks and reduce once remission achieved (Birmingham Vasculitis Activity Score - BVAS=0), asthma controlled (Asthma Control...
